Introduction
============

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and causes more than half a million mortalities each year, making it the third most common cause of cancer-associated mortality ([@b1-ol-0-0-4547]). Numerous prognostic factors, including tumor size, tumor quantity, cell differentiation, venous invasion, degree of inflammation and deregulated microRNAs (miRNA), have been identified for the recurrence of HCC, but the molecular mechanism of HCC carcinogenesis is not fully understood ([@b2-ol-0-0-4547]--[@b5-ol-0-0-4547]). In addition, emerging evidence suggests that components of the RNA interference pathway and miRNAs may be important in the carcinogenesis of HCC ([@b6-ol-0-0-4547]).

miRNAs are small noncoding RNAs, 18--25 nucleotides in length, which bind to the 3′-untranslated region of target mRNAs. This sequence-specific binding leads to target mRNA degradation or repression, resulting in decreased levels of encoded protein ([@b7-ol-0-0-4547],[@b8-ol-0-0-4547]). miRNAs have already been implicated as regulators of numerous physiological and pathological processes, including development, cell proliferation, differentiation and apoptosis, and tumor progression and metastasis ([@b9-ol-0-0-4547]). Dicer is a cytoplasmic RNaseIII enzyme that cleaves the loop of pri-miRNA and long double-stranded RNA into \~22 bp double-stranded miRNAs and short interfering RNAs. It is associated with the regulation of cell proliferation and control of apoptosis ([@b10-ol-0-0-4547],[@b11-ol-0-0-4547]). Increasing evidence has demonstrated that there is a low expression of Dicer in tumors, including breast, lung and ovarian cancer, neuroblastoma, human tongue squamous cell carcinoma, chronic lymphocytic leukemia and nasopharyngeal carcinoma, and that it is associated with a poor prognosis as a tumor suppressor ([@b12-ol-0-0-4547]--[@b23-ol-0-0-4547]). mRNA levels of Dicer have been reported to be significantly downregulated in non-viral HCC patients and this has predicted the outcome of patients with HCC in previous studies ([@b24-ol-0-0-4547],[@b25-ol-0-0-4547]). The present study assessed the protein expression levels of Dicer in HCC patients, the majority of whom had viral HCC, and evaluate its association with HCC outcome.

Materials and methods
=====================

### Tissue specimens

HCC tissues were obtained from 119 patients that underwent HCC resection at The Fourth Hospital of Hebei Medical University (Shijiazhuang, China) between March 2007 and September 2009. None of the patients had received chemotherapy prior to surgery. Adjacent non-tumor tissues were used as normal tissues for comparison to the HCC tissues. Tumor differentiation and pathological tumor stage were defined by the Edmondson grading system and the tumor-node-metastasis (TNM) classification of the International Union Against Cancer ([@b26-ol-0-0-4547]). The procedures of the present study were supervised and approved by the Human Tissue Research Committee of The Fourth Hospital of Hebei Medical University (approval no., 2007MEC-005), and written informed consent was obtained from all the patients.

### Immunohistochemistry

Serial tissue sections (4 µm thick) were deparaffinized with xylene, rehydrated, and subjected to microwave antigen retrieval in citrate buffer (pH, 6.0) for 20 min. Subsequently, 3% hydrogen peroxide (Invitrogen™; Thermo Fisher Scientific, Inc., Waltham, MA, USA) in methanol was used to quench endogenous peroxidase activity, followed by incubation with 1% bovine serum albumin (Pierce™; Thermo Fisher Scientific, Inc.) to block nonspecific binding. Sections were incubated with rabbit polyclonal anti-DICER (catalog no., ab93380; dilution, 1:100; Abcam, Cambridge, UK) overnight at 4°C. Subsequent to rinsing with phosphate buffer (pH, 7.2) three times, the slides were incubated with biotinylated secondary anti-rabbit IgG antibody for 20 min at room temperature and stained with 3,3′-diaminobenzidine (catalog no., kit-0017; Maixin Biotechnology Development, Co., Ltd., Fuzhou, China), according to the manufacturer\'s protocol. All the slides were counterstained with hematoxylin (Beijing Zhongshan Golden Bridge Biotechnology Co., Beijing, China), dehydrated and mounted with a coverslip using a standard medium. The slides were visualized using the Leica DM IL inverted microscope (Leica Microsystems GmbH, Wetzlar, Germany). Two independent pathologists, who were blinded to the study design, were employed to review the results and score all samples, using the HSCORE as described previously ([@b17-ol-0-0-4547],[@b27-ol-0-0-4547]). The staining intensity was scored as follows: 0, no staining; 1, weak staining, light-yellow; 2, moderate-weak staining, yellow brown; 3, moderate-strong staining, brown; and 4, strong staining, dark brown). The HSCORE represents the sum of each of the percentages multiplied by the weighted intensity of staining as follows: HSCORE = (i + 1) π, where i = 1, 2, 3 and 4, and π varies between 0 and 100%. A score of \>100 was defined as high expression and ≤100 as low expression ([Fig. 1](#f1-ol-0-0-4547){ref-type="fig"}).

### Cell culture and transfection

Human hepatocellular carcinoma HepG2 cell line was purchased from the Cell Resource Center, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences (Beijing, China). The cells were maintained as an adherent cell line in Dulbecco\'s modified Eagle\'s medium (DMEM; Gibco^®^; Thermo Fisher Scientific, Inc.) supplemented with 10% fetal bovine serum (Invitrogen™; Thermo Fisher Scientific, Inc.), 1X MEM Non-Essential Amino Acid, 2 mmol/l L-glutamine, 50 U/ml penicillin and 50 µg/ml streptomycin (all Gibco^®^; Thermo Fisher Scientific, Inc.) in a humidified atmosphere of 5% CO~2~ at 37°C. The pcDNA3.1-Dicer vector was a kindly donated by Professor Zhihong Zheng (China Medical University, Taichung, Taiwan). The HepG2 cells were transfected with pcDNA3.1 (+) (Invitrogen™; Thermo Fisher Scientific, Inc.) and pcDNA3.1 (+)-Dicer plasmids using Lipofectamine^®^ 2000 (Invitrogen™; Thermo Fisher Scientific, Inc.), which contained geneticin selective markers. Stable cells were harvested 8 weeks later using geneticin selection, and the results are represented as PC-control and PC-Dicer.

### Cell proliferation

Cell proliferation capacity was analyzed by Cell Counting kit-8 (CCK-8; Dojindo Molecular Technologies, Inc., Kumamoto, Japan) as described previously ([@b28-ol-0-0-4547]). Briefly, the cells were seeded into 96-well plates (Corning Incorporated, Corning, NY, USA) at a density of 10^3^ cells/well and incubated for 1--7 days under the conditions stated previously. In total, 10 µl CCK-8 was added to each well, according to manufacturer\'s protocol, followed by incubation at 37°C with 5% humidified CO~2~ for 2 h. The absorbance of the cells was measured at 450 nm with Thermo Multiskan™ Spectrum microplate reader (Thermo Fisher Scientific, Inc. CCK-8 allows sensitive colorimetric assays for the determination of cell proliferation by measuring dehydrogenases in viable cells. All assays were carried out independently three times.

### Cell migration and invasion assay

Stably transfected cells were harvested and resuspended in medium without fetal bovine serum and subsequently placed in the top chamber of a 24-well Transwell plate with 8 µm pore size (Costar Inc., Milpitas, CA, USA) at a density of 1×10^5^ cells/well. The lower chamber was filled with media supplemented with 10% fetal bovine serum. After 48 h, unmigrated cells were removed from the upper surface of the Transwell membrane using a cotton-tipped swab, and the migrated cells on the lower membrane surface were fixed with 90% alcohol and then stained with 0.05% crystal violet (Nanjing Chemical Technology Co., Ltd., Nanjing, China). The invasion assay was performed in the same way, with the exception that the membrane insert was coated with Matrigel (BD Biosciences, Franklin Lakes, NJ, USA) diluted in DMEM (dilution, 1:4). The migrated/invading cells were randomly counted under a Leica DM IL inverted microscope in 5 representative areas on each plate (magnification, ×200). The data are presented as the mean ± standard error of the mean from at least three independent experiments.

### Terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assay

Cell apoptosis was detected using 4′,6-diamidino-2-phenylindole dihydrochloride (DAPI; Solarbio Science and Technology Co., Ltd., Beijing, China) staining and TUNEL assay. TUNEL assays were performed using the *In Situ* Cell Death Detection kit (Roche Diagnostics, Basel, Switzerland), according to manufacturer\'s protocol. The cells were fixed in 4% paraformaldehyde (Nanjing Chemical Technology Co., Ltd.) at room temperature for 1 h, penetrated with 0.5% Triton X-100 (Amresco LLC, Solon, OH, USA) for 2 min on ice and then incubated with TUNEL reaction mixture for 1 h at 37°C. Positive fluorescence was detected at an excitation wavelength in the range of 570--620 nm (maximum, 580 nm; red) using a Leica DM IL inverted microscope. DAPI was excited with ultraviolet light. The experiment was repeated at least three times.

### Western blot analysis

Protein was isolated from cells using RIPA buffer (Beyotime Institute of Biotechnology, Haimen, China), according to the manufacturer\'s instructions. The protein concentration was measured by performing a BCA assay. Total protein (50 µg) was denatured by boiling for 5 min and was separated using 7% sodium dodecyl sulfate-polyacrylamide gel electrophoresis, then transferred onto a polyvinylidene difluoride membrane (Sigma-Aldrich, St. Louis, MO, USA). After blocking with 5% skim milk for 2 h, the membrane was incubated with primary antibody at 4°C overnight. Subsequently, the membrane was incubated with secondary antibody for 30 min at 37°C and washed by phosphate-buffered saline with Tween 20. Western blot analysis was performed with rabbit polyclonal anti-Dicer (dilution, 1:1,000; catalog no., ab93380; Abcam), rabbit monoclonal anti-B-cell lymphoma 2 (Bcl-2; dilution, 1:500; catalog no., AB112; Beyotime Institute of Biotechnology), mouse monoclonal anti-Bcl-2-like protein 4 (Bax; dilution, 1:500; catalog no., AB026; Beyotime Institute of Biotechnology) and rabbit polyclonal anti-β-actin (dilution, 1:500; catalog no., sc-7210; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) antibodies. An HRP-conjugated anti-rabbit IgG antibody was used as the secondary antibody (dilution, 1:2,000; catalog no., ZDR-5403; Beijing Zhongshan Golden Bridge Biotechnology Co.). Signals were detected using FluorChem^®^ HD2 (Alpha Innotech Corporation, San Leandro, CA, USA).

### Statistical analysis

Survival curves were calculated using the Kaplan-Meier method, and comparisons between the curves were made using the log-rank test. Multivariate survival analysis was performed using a Cox proportional hazards model. Data from the CCK-8, migration and invasion assay were compared using Student\'s t-test. A two-tailed value of P\<0.05 was considered to indicate a statistically significant difference. Statistical analysis was performed using SPSS version 15.0 software (SPSS, Inc., Chicago, IL, USA).

Results
=======

### Clinical characteristics of patients with HCC

A total of 119 patients were enrolled in the present study, which consisted of 32 non-viral HCC patients, 82 hepatitis B (HBV)-associated HCC patients, 3 hepatitis C (HCV)-associated HCC patients and 2 HCC patients with HCV and HBV infections. The patients were followed up every 3 months for 3 years, using routin radiological and biochemical examination. Survival was measured between the day of surgery and the date of recurrence, metastasis and mortality. The association between the data collected during the 3-year follow-up and the patients\' clinical characteristics was analyzed using the log-rank test with the Kaplan-Meier method. Gender, age, tumor quantity and child classification (Child-Pugh grade) ([@b29-ol-0-0-4547]) were not statistically significant predictors of postoperative survival time; however, tumor size, TNM classification and portal vein thrombosis were associated with survival time in these patients ([Table I](#tI-ol-0-0-4547){ref-type="table"}).

### Dicer expression in HCC tissues, and its association with HCC survival

Dicer staining was observed in the cytoplasm of cells in immunohistochemically stained HCC tissues ([Fig. 1](#f1-ol-0-0-4547){ref-type="fig"}). A reduced expression of Dicer (HSCORE 60) was observed in cancerous tissues compared with adjacent non-cancerous tissues (HSCORE 360). The patients with HCC were divided into two groups on the basis of Dicer expression levels: High expression, n=66; low expression, n=53. Postoperative survival curves were plotted using the Kaplan-Meier method for the high and low Dicer groups, and the results demonstrated that the 3-year survival rates of patients were 63.6% for the high expression group and 30.2% for the low expression group. Patients in the low Dicer expression group were associated with a shorter survival time compared with patients in the high Dicer expression group (P\<0.001; [Fig. 2](#f2-ol-0-0-4547){ref-type="fig"}).

Multivariate analysis was performed using Cox proportional hazards model for various predictive factors. As shown in [Table I](#tI-ol-0-0-4547){ref-type="table"}, Dicer expression was identified as an independent predictor of HCC outcome \[relative risk (RR), 0.660; 95% confidence interval, 0.506--0.861; P=0.002\]. Size of the tumor (RR, 2.608; 95% CI, 1.429--4.760; P=0.002), portal vein thrombosis (RR, 2.870; 95% CI, 1.552--5.307; P=0.001), gender (RR, 2.612; 95% CI, 1.008--6.772; P=0.048) and tumor quantity (RR, 2.870; 95% CI, 1.552--5.307; P=0.001) were also identified as independent predictive factors for HCC outcome. These data demonstrate that Dicer expression is a clear predictive factor for the outcome of HCC patients.

### Dicer inhibits proliferation and induces apoptosis of HCC cells

A CCK-8 assay was performed to measure the proliferation capacity of the HepG2 cells. Cell viability in HepG2 cells overexpressing Dicer was significantly reduced compared with control cells between day 3 and 7 ([Fig. 3A and B](#f3-ol-0-0-4547){ref-type="fig"}; day 1, P=0.077; day 2, P=0.068; day 3, P=0.001; day 4, P=0.004; day 5, P=0.008; day 6, P=0.002; day 7, P=0.001). To elucidate the potential mechanisms of this growth inhibition by Dicer, expression of apoptosis-associated factors Bax and Bcl-2 were assessed using western blot analysis, and a TUNEL assay was performed. Protein levels of Bcl-2 were significantly reduced whereas Bax protein levels were markedly elevated in the PC-Dicer HCC cells. The presence of TUNEL-positive cells (stained red) also revealed that DNA strand breaks occurred in HepG2 cells transfected with PC-Dicer ([Fig. 3C and D](#f3-ol-0-0-4547){ref-type="fig"}). These data indicate that Dicer inhibits the proliferation and promotes the apoptosis of HCC cells.

### Dicer overexpression suppressed the migration and invasion of HCC cells

As migration and invasion is an important factor for tumor metastasis, the effects of Dicer overexpression on cell migration and invasion was evaluated using Transwell assays. The results demonstrated that compared with the control cells, PC-Dicer stably transfected cells had significantly decreased migration (P\<0.01) and invasion (P\<0.05) capacities ([Fig. 4](#f4-ol-0-0-4547){ref-type="fig"}). Overexpression of Dicer reduced the migration capacity of cells by \~70% and invasive capacity by \~45% in Dicer overexpressed HepG2 cells compared with control cells.

Discussion
==========

A reduction of miRNA expression has been identified in various cancer models using miRNA expression profiling analyses, which has led to the generation of the hypothesis that miRNA processing machinery genes, including Dicer, are deregulated in tumor tissues ([@b30-ol-0-0-4547]). Low Dicer expression has been revealed to be associated with advanced tumor stages and poor clinical outcome in numerous types of cancer ([@b16-ol-0-0-4547]--[@b23-ol-0-0-4547],[@b31-ol-0-0-4547],[@b32-ol-0-0-4547]). However, controversial data has been obtained in certain types of cancer; Dicer has been observed to be upregulated in prostate adenocarcinoma, ovarian serous carcinoma and colorectal cancer ([@b33-ol-0-0-4547]--[@b36-ol-0-0-4547]).

The present study evaluated the protein level of Dicer in HCC tissue to investigate its association with HCC tumorigenesis. Consistent with previous reports that demonstrated that there is reduced Dicer mRNA expression in nonviral HCC patients ([@b25-ol-0-0-4547]), the present study revealed that there were reduced Dicer protein levels in viral HCC patients, and that the expression of Dicer was associated with postoperative HCC survival as a tumor suppressor gene. The potential mechanism of Dicer in HCC may be explained to a certain degree by the present functional assay data, which indicated that Dicer inhibited the proliferation, migration and invasion and promoted the apoptosis of HCC cells. The present data corroborates previous observations that Dicer C-terminal fragment possesses DNase activity that is critical for DNA fragmentation during apoptosis ([@b37-ol-0-0-4547]).

A previous study using a miRNA microarray was performed to identify candidate miRNAs regulated by Dicer using a small HCC sample size ([@b38-ol-0-0-4547]). That study demonstrated that the miRNA expression profiling was downregulated in tissues that had a low expression of Dicer. Proliferative and apoptotic (mitogen-activated protein kinases and Wnt), adhesive (cell adhesion molecules and adherens junction) and survival (ErbB) signaling pathways appeared to be involved in HCC tumorigenesis through Dicer mediation (data not shown). Angiogenesis is a novel target for cancer therapy; however, the expression of the angiogenesis associated factors vascular endothelial growth factor and E-cadherin in HepG2 cells were not altered during Dicer overexpression ([@b39-ol-0-0-4547]).

In conclusion, the present study demonstrated that Dicer is important in HCC progression by mediating the proliferation, apoptosis and metastasis of HCC cells. Therefore, additional study to understand the mechanism of Dicer in HCC is crucial in the development of novel methods for the diagnosis and prognosis of this disease.

The present study was supported by Key Basic Research Program of Hebei (grant nos. 14967713D and 13967607D).
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![Dicer inhibits the proliferation and induces apoptosis in hepatocellular carcinoma HepG2 cells. (A) Identification of Dicer expression in PC-control and PC-Dicer transfected HepG2 cells. (B) Cell viability was measured using cell counting kit-8 assay. Data are presented as the mean ± standard error of the mean of three independent experiments. \*\*P\<0.01 vs. PC-control cells. (C) Protein expression of Bax and Bcl-2 was evaluated by western blot analysis. (D) Cell apoptosis was observed by TUNEL assay. HepG2 cells transfected with PC-control and PC-Dicer were stained with TUNEL and viewed under a fluorescence microscope (magnification, ×200; scale bar, 200 µm). MW, molecular weight; Bcl-2, B-cell lymphoma 2; Bax, Bcl-2-like protein 4; DAPI, 4′,6-diamidino-2-phenylindole dihydrochloride; TUNEL, terminal deoxynucleotidyl transferase dUTP nick-end labeling.](ol-11-06-3961-g02){#f3-ol-0-0-4547}
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###### 

Univariate analysis of clinical characteristics associated with postoperative survival in patients with hepatocellular carcinoma.

  Characteristic           n      3-year survival rate, %   P-value
  ------------------------ ------ ------------------------- ---------
  Total                    119                              
  Gender                                                      0.269
    Male                   106    47.2                      
    Female                   13   61.5                      
  Age, years                                                  0.485
    ≤55                      61   45.9                      
    \>55                     58   51.7                      
  Tumor size, cm                                            \<0.010
    ≤5                       52   69.2                      
    \>5                      67   32.8                      
  Tumor quantity                                              0.468
    Single                   96   50.0                      
    Multiple                 23   43.5                      
  Child classification                                        0.258
    A                      110    50.0                      
    B                        9    33.3                      
  TNM classification                                        \<0.010
    I                        43   74.4                      
    II                       70   35.7                      
    III                      6    16.7                      
  Portal vein thrombosis                                    \<0.010
    Yes                      16     6.3                     
    No                     103    55.3                      
  Dicer expression                                          \<0.010
    High                     66   63.6                      
    Low                      53   30.2                      

Tumor size was measured by diameter. Statistical analysis was calculated using the log-rank test. TNM, tumor-node-metastasis.

###### 

Multivariate analysis of prognostic factors associated with postoperative survival in patients with hepatocellular carcinoma.

  Characteristic                  RR      95% CI         P-value
  ------------------------------- ------- -------------- ---------
  Tumor size, ≤5 vs. \>5 cm       2.608   1.429--4.760   0.002
  TNM, I vs. II vs. III           1.781   0.678--4.682   0.242
  PVT, yes vs. no                 2.870   1.552--5.307   0.001
  Dicer expression, igh vs. low   0.660   0.506--0.861   0.002
  Gender, male vs. female         2.612   1.008--6.772   0.048
  Age, ≤55 vs. \>55 years         0.744   0.439--1.260   0.271
  Tumors, single vs. multiple     2.870   1.552--5.307   0.001
  Child classification, A vs. B   1.560   0.640--3.803   0.328

Statistical analysis calculated using Cox proportional hazards model. TNM, tumor-node-metastasis; PVT, portal vein thrombosis; RR, relative risk; CI, confidence interval.
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